$41.59
-0.25[-0.60%]
At close: Apr 26
$41.59
0[0.00%]
After Hours: 4:20PM EDT
Ionis Pharmaceuticals
(NASDAQ:IONS)Latest News for Ionis Pharmaceuticals Stock (NASDAQ:IONS)
Ionis Pharmaceuticals Stock (NASDAQ: IONS)
Categories: All
Wednesday, April 10, 2024
Tuesday, April 09, 2024
- The Latest Analyst Ratings For Ionis PharmaceuticalsBenzinga Insights - Apr 9, 2024, 11:01AM
- Oppenheimer Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $75Benzinga Newsdesk - Apr 9, 2024, 8:27AM
- Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price TargetBenzinga Newsdesk - Apr 9, 2024, 6:34AM
Monday, March 25, 2024
Wednesday, March 13, 2024
- Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data ShowsVandana Singh - Mar 13, 2024, 9:52AM
- Ionis Pharmaceuticals shares are trading higher after the company announced results from its Phase 2 study of ION224.Benzinga Newsdesk - Mar 13, 2024, 7:46AM
- Ionis Announces Results from Phase 2 Study of ION224, an Investigational Medicine Demonstrating Clinical Efficacy in the Treatment of NASH/MASHBenzinga Newsdesk - Mar 13, 2024, 7:03AM
Wednesday, March 06, 2024
- Oppenheimer Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $72Benzinga Newsdesk - Mar 6, 2024, 8:57AM
- Biogen Announced Interim 6-month Biomarker Data From Respond Study Of Spinraza In Infants And Toddlers With Spinal Muscular Atrophy After Zolgensma Treatment, Data Shows That Plasma Neurofilament Light Chain Were Reduced In Nearly All Study ParticipantsBenzinga Newsdesk - Mar 6, 2024, 7:42AM
Monday, February 26, 2024
Thursday, February 22, 2024
Wednesday, February 21, 2024
- Ionis Pharmaceuticals Forecasts Full Year 2024 Revenue Guidance Of Over $575M Versus Consensus Of $635.31M, With Adjusted Operating Loss Of Less Than $(475)M And Cash, Cash Equivalents And Short-term Investments Of Around $1.7BBenzinga Newsdesk - Feb 21, 2024, 7:09AM
- Ionis Pharmaceuticals Q4 Adjusted EPS $0.12 May Not Be Comparable To $(0.83) Estimate, Sales $325.00M Not Be Comparable To $174.76M EstimateBenzinga Newsdesk - Feb 21, 2024, 7:04AM
- Earnings Scheduled For February 21, 2024Benzinga Insights - Feb 21, 2024, 5:09AM
Thursday, February 15, 2024
Thursday, February 08, 2024
Thursday, February 01, 2024
Wednesday, January 31, 2024
Friday, January 26, 2024
Monday, January 22, 2024
- Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels StudyVandana Singh - Jan 22, 2024, 2:35PM
- Ionis Pharmaceuticals Announced Topline Results For The Phase 3 OASIS-HAE Study Of Donidalorsen In People With Hereditary Angioedema, Meeting The Primary Endpoint Of Reduction In Rate Of Angioedema Attacks Compared To PlaceboBenzinga Newsdesk - Jan 22, 2024, 7:12AM
Thursday, January 18, 2024
Monday, January 08, 2024
- Praxis Precision Medicines Provides Update On Advancing Clinical Stage Portfolio; Recently Announced Licensing Partnership With Tenacia Biotechnology To Develop And Commercialize Ulixacaltamide In Greater China With Total Consideration Over $275MBenzinga Newsdesk - Jan 8, 2024, 8:25AM
- Ionis Pharmaceuticals Highlights The Company's 2023 Achievements And Previewed Milestones Expected In 2024 At The 42nd Annual J.P. Morgan Healthcare ConferenceBenzinga Newsdesk - Jan 8, 2024, 7:13AM
Thursday, January 04, 2024
Tuesday, January 02, 2024
- 10 Health Care Stocks Whale Activity In Today's SessionBenzinga Insights - Jan 2, 2024, 12:35PM
- Ionis Pharmaceuticals shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $52 to $62.Benzinga Newsdesk - Jan 2, 2024, 10:05AM
- B of A Securities Upgrades Ionis Pharmaceuticals to Buy, Raises Price Target to $62Benzinga Newsdesk - Jan 2, 2024, 7:37AM
Friday, December 22, 2023
- Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M PotentialVandana Singh - Dec 22, 2023, 12:04PM
- New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis TreatmentVandana Singh - Dec 22, 2023, 7:49AM
- Reported Earlier, AstraZeneca And Ionis' WAINUA™ Granted Regulatory Approval In The U.S. For The Treatment Of Adults With Polyneuropathy Of Hereditary Transthyretin-Mediated AmyloidosisBenzinga Newsdesk - Dec 22, 2023, 1:35AM
Tuesday, December 19, 2023
Monday, December 18, 2023
- Ionis Pharmaceuticals Enters License Agreement With Otsuka Pharmaceutical Under Which Otsuka Obtained Exclusive Europe Rights To Commercialize Donidalorsen; Ionis Will Receive$65M In Upfront Payments And Milestones Based On Regulatory And Sales TargetsBill Haddad - Dec 18, 2023, 4:03PM
- Stifel Maintains Hold on Ionis Pharmaceuticals, Raises Price Target to $50Benzinga Newsdesk - Dec 18, 2023, 10:36AM
Friday, November 17, 2023
Sunday, November 12, 2023
Thursday, November 09, 2023
Friday, November 03, 2023
Thursday, November 02, 2023
- Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS BeatBenzinga Neuro - Nov 2, 2023, 10:27PM
- EVP at Ionis Pharmaceuticals Acquires Company Stock Options Worth 2,400 SharesBenzinga Insights - Nov 2, 2023, 11:00AM
- Ionis' Q3 Cash, Cash Equivalents And Short-Term Investments Reached $2.2BBenzinga Newsdesk - Nov 2, 2023, 7:27AM